Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Coloplast tumbles after soft Q1 hit by reimbursement disruption at Kerecis (Investing.com) +++ COLOPLAST Aktie -4,45%

ILLUMINA Aktie

 >ILLUMINA Aktienkurs 
103 EUR    -9.1%    (Tradegate)
Ask: 103 EUR / 100 Stück
Bid: 102 EUR / 60 Stück
Tagesumsatz: 2322 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ILLUMINA Aktie über LYNX handeln
>ILLUMINA Performance
1 Woche: -7,9%
1 Monat: -5,1%
3 Monate: +6,4%
6 Monate: +34,8%
1 Jahr: -5,1%
laufendes Jahr: -0,4%
>ILLUMINA Aktie
Name:  ILLUMINA INC. DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US4523271090 / 927079
Symbol/ Ticker:  ILU (Frankfurt) / ILMN (NASDAQ)
Kürzel:  FRA:ILU, ETR:ILU, ILU:GR, NASDAQ:ILMN
Index:  S&P500
Webseite:  http://www.illumina.com/
Profil:  Illumina, Inc. operates as a global leader in the ..
>Volltext..
Marktkapitalisierung:  18254.49 Mio. EUR
Unternehmenswert:  19358.31 Mio. EUR
Umsatz:  3627.25 Mio. EUR
EBITDA:  943 Mio. EUR
Nettogewinn:  595.09 Mio. EUR
Gewinn je Aktie:  3.79 EUR
Schulden:  2180.58 Mio. EUR
Liquide Mittel:  888.82 Mio. EUR
Operativer Cashflow:  949.77 Mio. EUR
Bargeldquote:  0.65
Umsatzwachstum:  -7.39%
Gewinnwachstum:  -
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  ILLUMINA
Letzte Datenerhebung:  06.02.26
>ILLUMINA Kennzahlen
Aktien/ Unternehmen:
Aktien: 152.8 Mio. St.
Frei handelbar: 97.19%
Rückkaufquote: 3.12%
Mitarbeiter: 10370
Umsatz/Mitarb.: 0.36 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 0.58%
Bewertung:
KGV: 29.98
KGV lG: 28.31
KUV: 5.04
KBV: 8.6
PEG-Ratio: -
EV/EBITDA: 20.53
Rentabilität:
Bruttomarge: 66.79%
Gewinnmarge: 16.41%
Operative Marge: 19.58%
Managementeffizenz:
Gesamtkaprendite: 11.53%
Eigenkaprendite: 31.2%
>ILLUMINA Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung
 
06.02.26 - 02:30
Illumina (ILMN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
 
While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....
06.02.26 - 02:18
Illumina outlines 2026 revenue guidance of $4.5B–$4.6B while advancing clinical growth and multiomics strategy (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.02.26 - 01:45
Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates (Zacks)
 
Illumina (ILMN) delivered earnings and revenue surprises of +7.42% and +0.35%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...
06.02.26 - 00:01
Earnings Call Transkript: Illumina übertrifft EPS-Prognose für Q4 2025 um 10,66 % (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
06.02.26 - 00:00
Illumina (ILMN) Q4 2025 Earnings Call Transcript (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
05.02.26 - 23:12
Illumina Inc. Q4 Profit Advances (AFX)
 
SAN DIEGO (dpa-AFX) - Illumina Inc. (ILMN) released earnings for its fourth quarter that Increases, from the same period last yearThe company's bottom line came in at $334 million, or $2.16 per sh......
05.02.26 - 22:09
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 (PR Newswire)
 
Fourth quarter 2025 results: Revenue of $1.16 billion, up 5% from Q4 2024 (up 4% on a constant currency basis) Ex-China revenue of $1.10 billion, up 8% from Q4 2024 (up 7% on a constant currency basis) GAAP operating margin of 17.4% and non-GAAP operating margin of 23.7% GAAP diluted EPS......
03.02.26 - 15:18
Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally (PR Newswire)
 
Illumina will sequence up to 4,000 unique individual animals across 1,300 species, unlock genomic insights from 50-year-old biological samples Sequencing connects decades of preserved biodiversity with the latest multiomic technologies SAN DIEGO, Feb. 3, 2026 /PRNewswire/ -- Illumina, Inc.......
02.02.26 - 15:09
PacBio Completes Sale of Short-Read Sequencing Assets (GlobeNewswire EN)
 
MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select intellectual property and other assets related to PacBio's short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina, Inc....
30.01.26 - 15:39
Illumina finishes SomaLogic acquisition (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.01.26 - 15:12
Standard BioTools Completes Sale of SomaLogic to Illumina (GlobeNewswire EN)
 
Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments...
30.01.26 - 15:06
Illumina completes acquisition of SomaLogic (PR Newswire)
 
Deeply expands leadership in proteomics and multiomics Combined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination leverages SomaScan with Illumina's NGS ecosystem, DRAGEN software, and Illumina Connected Multiomics to rapidly transform......
30.01.26 - 10:39
AKTIONÄR-Tipp GRAIL: Wichtiger Meilenstein für Krebstest – Massenmarkt im Blick (Der Aktionaer)
 
Seit vielen Jahren tüftelt GRAIL an seinem Multikrebstest Galleri. Der Test des Flüssigbiopsie-Spezialisten, der aus dem Genomsequenzierungsurgestein Illumina hervorgegangen ist, hat bereits im Jahr 2018 von der FDA die Auszeichnung "bahnbrechendes Medizinprodukt" erhalten....
29.01.26 - 17:30
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week′s Release (Zacks)
 
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
20.01.26 - 16:01
Illumina Gets Reimbursement For FDA-Approved TruSight Oncology Comprehensive Test, Stock Down (AFX)
 
SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Tuesday announced that the Centers for Medicare and Medicaid Services or CMS has granted reimbursement for the company's FDA-approved in vitro diagnost......
20.01.26 - 15:18
Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology (PR Newswire)
 
The FDA-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test, helping to advance adoption in the US healthcare system SAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that reimbursement has been granted for......
19.01.26 - 13:42
Cathie Wood′s weekly update: buys Broadcom, AMD; sells Tesla, Illumina (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
14.01.26 - 01:24
Stocks Slide on CPI, Traders Boost June Fed Rate-Cut Odds | The Close 1/13/2026 (Bloomberg)
 
Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after the closing bell on Wall Street. Today's guests are Former Boston Fed President Eric Rosengren, U.S. Bancorp's Stephen Philipson, BNY Mellon's Dermot McDonogh, Inflation Insights' Omair Sharif, Teva Pharmaceutical's Richard Francis, Gabelli's Macrae Sykes, AstraZeneca's Aradhana Sarin, Novo Nordisk's Mike Doustdar, Illumina's Jacob Thaysen, Former Kansas City Fed President Thomas Hoenig, Fabletics' Meera Bhatia. (Source: Bloomberg)...
13.01.26 - 23:01
Illumina CEO Sees Big Growth Opportunity in China (Bloomberg)
 
Illumina CEO Jacob Thaysen discusses the company's opportunities in the China market and the possibility of being acquired with Katie Greifeld at the JPMorgan Health-Care Conference in San Francisco. (Source: Bloomberg)...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer immer sich zu mir bekennt vor den Menschen, zu dem werde auch ich mich bekennen vor meinem Vater in den Himmeln. - Neues Testament: Evangelium nach Matthäus
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!